Northpointe Capital LLC decreased its stake in shares of NeoGenomics Inc. (NASDAQ:NEO) by 7.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 475,747 shares of the company’s stock after selling 40,612 shares during the period. Northpointe Capital LLC’s holdings in NeoGenomics were worth $3,825,000 as of its most recent SEC filing.
Several other institutional investors have also recently made changes to their positions in the stock. Uniplan Investment Counsel Inc. raised its position in NeoGenomics by 0.3% in the first quarter. Uniplan Investment Counsel Inc. now owns 821,860 shares of the company’s stock valued at $5,539,000 after buying an additional 2,710 shares during the period. State Street Corp raised its position in NeoGenomics by 0.9% in the first quarter. State Street Corp now owns 777,559 shares of the company’s stock valued at $5,241,000 after buying an additional 7,266 shares during the period. Geode Capital Management LLC raised its position in NeoGenomics by 3.8% in the first quarter. Geode Capital Management LLC now owns 355,158 shares of the company’s stock valued at $2,393,000 after buying an additional 13,052 shares during the period. Fox Run Management L.L.C. bought a new position in NeoGenomics during the second quarter valued at about $171,000. Finally, Falcon Point Capital LLC raised its position in NeoGenomics by 12.5% in the second quarter. Falcon Point Capital LLC now owns 209,538 shares of the company’s stock valued at $1,685,000 after buying an additional 23,216 shares during the period. Hedge funds and other institutional investors own 77.20% of the company’s stock.
NeoGenomics Inc. (NASDAQ:NEO) traded up 1.80% during midday trading on Tuesday, hitting $8.22. The company had a trading volume of 359,175 shares. The company’s market cap is $640.28 million. NeoGenomics Inc. has a 12 month low of $5.49 and a 12 month high of $9.54. The firm has a 50-day moving average price of $8.11 and a 200-day moving average price of $8.09.
NeoGenomics (NASDAQ:NEO) last posted its earnings results on Tuesday, July 26th. The company reported $0.04 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.03 by $0.01. NeoGenomics had a positive return on equity of 3.18% and a negative net margin of 3.76%. The firm had revenue of $63.10 million for the quarter, compared to analyst estimates of $61.07 million. During the same quarter in the prior year, the company earned $0.01 EPS. NeoGenomics’s revenue was up 159.0% on a year-over-year basis. Equities analysts anticipate that NeoGenomics Inc. will post $0.13 EPS for the current year.
Several equities analysts have issued reports on NEO shares. Benchmark Co. lifted their target price on NeoGenomics from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday, July 27th. Zacks Investment Research upgraded NeoGenomics from a “hold” rating to a “buy” rating and set a $9.25 target price on the stock in a research note on Friday, August 5th. Craig Hallum reiterated a “buy” rating on shares of NeoGenomics in a research note on Saturday, July 9th. BTIG Research restated a “buy” rating and set a $10.00 price target on shares of NeoGenomics in a research note on Friday, July 8th. Finally, Raymond James Financial Inc. started coverage on NeoGenomics in a research note on Thursday, September 8th. They set an “outperform” rating and a $10.00 price target on the stock. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $10.41.
In related news, insider Maher Albitar sold 60,075 shares of the stock in a transaction dated Monday, September 12th. The stock was sold at an average price of $8.23, for a total transaction of $494,417.25. Following the transaction, the insider now owns 165,375 shares of the company’s stock, valued at approximately $1,361,036.25. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 12.20% of the company’s stock.
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics Inc. (NASDAQ:NEO).
Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.